Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

por Barouch, Dan H., Stephenson, Kathryn E., Sadoff, Jerald, Yu, Jingyou, Chang, Aiquan, Gebre, Makda, McMahan, Katherine, Liu, Jinyan, Chandrashekar, Abishek, Patel, Shivani, Le Gars, Mathieu, de Groot, Anne M., Heerwegh, Dirk, Struyf, Frank, Douoguih, Macaya, van Hoof, Johan, Schuitemaker, Hanneke
Publicado 2021

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )

por Le Gars, Mathieu, Sadoff, Jerald, Struyf, Frank, Heerwegh, Dirk, Truyers, Carla, Hendriks, Jenny, Gray, Glenda, Grinsztejn, Beatriz, Goepfert, Paul A, Schuitemaker, Hanneke, Douoguih, Macaya
Publicado 2022

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19

por Barouch, Dan H., Stephenson, Kathryn E., Sadoff, Jerald, Yu, Jingyou, Chang, Aiquan, Gebre, Makda, McMahan, Katherine, Liu, Jinyan, Chandrashekar, Abishek, Patel, Shivani, Le Gars, Mathieu, de Groot, Anne Marit, Heerwegh, Dirk, Struyf, Frank, Douoguih, Macaya, van Hoof, Johan, Schuitemaker, Hanneke
Publicado 2021

LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials

por Le Gars, Mathieu, Sadoff, Jerald, Jongeneelen, Mandy, Heerwegh, Dirk, Shukarev, Georgi, Truyers, Carla, de Groot, Anne Marit, Scheper, Gert, Hendriks, Jenny, Brandenburg, Boerries, Struyf, Frank, Van Hoof, Johan, Douoguih, Macaya, Schuitemaker, Hanneke
Publicado 2021

Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial

por Fong, Youyi, McDermott, Adrian B., Benkeser, David, Roels, Sanne, Stieh, Daniel J., Vandebosch, An, Gars, Mathieu Le, Van Roey, Griet A., Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Amoa-Awua, Obrimpong, Basappa, Manjula, Flach, Britta, Lin, Bob C., Moore, Christopher, Naisan, Mursal, Naqvi, Muhammed, Narpala, Sandeep, O’Connell, Sarah, Mueller, Allen, Serebryannyy, Leo, Castro, Mike, Wang, Jennifer, Petropoulos, Christos J., Luedtke, Alex, Hyrien, Ollivier, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars W. P., Hejazi, Nima S., Kenny, Avi, Carone, Marco, Wolfe, Daniel N., Sadoff, Jerald, Gray, Glenda E., Grinsztejn, Beatriz, Goepfert, Paul A., Little, Susan J., de Sousa, Leonardo Paiva, Maboa, Rebone, Randhawa, April K., Andrasik, Michele P., Hendriks, Jenny, Truyers, Carla, Struyf, Frank, Schuitemaker, Hanneke, Douoguih, Macaya, Kublin, James G., Corey, Lawrence, Neuzil, Kathleen M., Carpp, Lindsay N., Follmann, Dean, Gilbert, Peter B., Koup, Richard A., Donis, Ruben O.
Publicado 2022

Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in in...

por Ong-Lim, Anna Lisa, Shukarev, Georgi, Trinidad-Aseron, Mitzi, Caparas-Yu, Delia, Greijer, Astrid, Duchene, Michel, Scheper, Gert, van Paassen, Vitalija, Le Gars, Mathieu, Cahill, Conor P., Schuitemaker, Hanneke, Douoguih, Macaya, Jacquet, Jeanne-Marie
Publicado 2022

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

por Alter, Galit, Yu, Jingyou, Liu, Jinyan, Chandrashekar, Abishek, Borducchi, Erica N., Tostanoski, Lisa H., McMahan, Katherine, Jacob-Dolan, Catherine, Martinez, David R., Chang, Aiquan, Anioke, Tochi, Lifton, Michelle, Nkolola, Joseph, Stephenson, Kathryn E., Atyeo, Caroline, Shin, Sally, Fields, Paul, Kaplan, Ian, Robins, Harlan, Amanat, Fatima, Krammer, Florian, Baric, Ralph S., Le Gars, Mathieu, Sadoff, Jerald, de Groot, Anne Marit, Heerwegh, Dirk, Struyf, Frank, Douoguih, Macaya, van Hoof, Johan, Schuitemaker, Hanneke, Barouch, Dan H.
Publicado 2021

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

por Sadoff, Jerald, Le Gars, Mathieu, Shukarev, Georgi, Heerwegh, Dirk, Truyers, Carla, de Groot, Anne M., Stoop, Jeroen, Tete, Sarah, Van Damme, Wim, Leroux-Roels, Isabel, Berghmans, Pieter-Jan, Kimmel, Murray, Van Damme, Pierre, de Hoon, Jan, Smith, William, Stephenson, Kathryn E., De Rosa, Stephen C., Cohen, Kristen W., McElrath, M. Juliana, Cormier, Emmanuel, Scheper, Gert, Barouch, Dan H., Hendriks, Jenny, Struyf, Frank, Douoguih, Macaya, Van Hoof, Johan, Schuitemaker, Hanneke
Publicado 2021

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

por Sadoff, Jerald, Gray, Glenda, Vandebosch, An, Cárdenas, Vicky, Shukarev, Georgi, Grinsztejn, Beatriz, Goepfert, Paul A., Truyers, Carla, Van Dromme, Ilse, Spiessens, Bart, Vingerhoets, Johan, Custers, Jerome, Scheper, Gert, Robb, Merlin L., Treanor, John, Ryser, Martin F., Barouch, Dan H., Swann, Edith, Marovich, Mary A., Neuzil, Kathleen M., Corey, Lawrence, Stoddard, Jeffrey, Hardt, Karin, Ruiz-Guiñazú, Javier, Le Gars, Mathieu, Schuitemaker, Hanneke, Van Hoof, Johan, Struyf, Frank, Douoguih, Macaya
Publicado 2022

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials

por Sadoff, Jerald, Le Gars, Mathieu, Brandenburg, Boerries, Cárdenas, Vicky, Shukarev, Georgi, Vaissiere, Nathalie, Heerwegh, Dirk, Truyers, Carla, de Groot, Anne Marit, Jongeneelen, Mandy, Kaszas, Krisztian, Tolboom, Jeroen, Scheper, Gert, Hendriks, Jenny, Ruiz-Guiñazú, Javier, Struyf, Frank, Van Hoof, Johan, Douoguih, Macaya, Schuitemaker, Hanneke
Publicado 2022

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

por Sadoff, Jerald, Gray, Glenda, Vandebosch, An, Cárdenas, Vicky, Shukarev, Georgi, Grinsztejn, Beatriz, Goepfert, Paul A., Truyers, Carla, Fennema, Hein, Spiessens, Bart, Offergeld, Kim, Scheper, Gert, Taylor, Kimberly L., Robb, Merlin L., Treanor, John, Barouch, Dan H., Stoddard, Jeffrey, Ryser, Martin F., Marovich, Mary A., Neuzil, Kathleen M., Corey, Lawrence, Cauwenberghs, Nancy, Tanner, Tamzin, Hardt, Karin, Ruiz-Guiñazú, Javier, Le Gars, Mathieu, Schuitemaker, Hanneke, Van Hoof, Johan, Struyf, Frank, Douoguih, Macaya
Publicado 2021

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 tr...

por Hardt, Karin, Vandebosch, An, Sadoff, Jerald, Le Gars, Mathieu, Truyers, Carla, Lowson, David, Van Dromme, Ilse, Vingerhoets, Johan, Kamphuis, Tobias, Scheper, Gert, Ruiz-Guiñazú, Javier, Faust, Saul N, Spinner, Christoph D, Schuitemaker, Hanneke, Van Hoof, Johan, Douoguih, Macaya, Struyf, Frank
Publicado 2022